Control of calcium metabolism

Calcium and phosphorus homeostasis

Primary elements of blood tissue are calcium (Ca) and phosphorus (P).

- up to 65 % of bone weight
- almost all Ca and P supply, half of supply of Mg in human body
- Essential role of these elements in physiological processes

Bone tissue

- 99 % of overall Ca, of it 99 % in mineral component
- 1 % quickly mobilizable and convertible (ICF - ECF)

Extracellular	Calcium ions	Phosphate ions
Concentration total, in serum free	$2.5 \times 10^{-3} \text{M}$ $1.2 \times 10^{-3} \text{M}$	$1.00 imes 10^{-3} M$ $0.85 imes 10^{-3} M$
Functions	Bone mineral Blood coagulation Membrane excitability	Bone mineral
Intracellular		
Concentration	$10^{-7} \mathrm{M}$	$1-2 imes 10^{-3} \mathrm{M}$
Functions	Signal for: • Neuron activation • Hormone secretion • Muscle contraction	 Structural role High energy bonds Regulation of proteins by phosphorylation


Extra- and intracellular calcium

Extracellular calcium

- Cartilage and bone mineralization
- Cofactor of enzymes including proteins of coagulation cascade
- "Source" of intracellular calcium
- Excitable tissues

Intracellular calcium

- Signaling role
- Contractility
- Excitability
- Neurosecretion
- Endocrine and exocrine secretion
- Cell differentiation and proliferation
- Cell death and its regulation



Calcium and its intake

Calcium absorption


- 25 60 %
- Age
- Dietary habits and calcium content in diet
- Bone tissue requirements
- Vitamin D

Stomach

- Gastric juice and role of HCl
- Signalization connected to HCl production


Small intestine

- Duodenum a jejunum 90 %
- Adaptive intake duodenum and ileum



Bone tissue is crucial calcium and phosphorus storage tissue. Age-related negative calcium balance is an osteoporosis risk factor.

Mechanisms of calcium absorption





Paracellular

- Luminal electrochemical gradient
- Integrity of intercellular connections
- Claudins and their role in paracellular transport

Transcellular


- TRPV6 and associated proteins
- Recyclation of TRPV6
- Alternative mechanisms?








Prolactin




Calcium on blood (calcemia)



Calcium excretion

- 98 % of filtered Ca is reabsorbed
- 70 % proximal tubule
- 20 % thick ascending limb of HL
- 5 % collecting duct
- 2 % urine
- CaSR (TALH)
- Paracellin-1
- PTH



Phosphorus

Distribution

- Bones cca 45 % $Ca_{10}(PO_4)_6(OH)_2$
- Organic and inorganic form in ICF and ECF
- Age, sex, growth

Blood


- Concentration 1 mM (serum)
- Ionized form (HPO₄²⁻, H₂PO₄-)
- 12 % protein complexes
- Intracellular concentration approximately same as extracellular
- Cotransport with sodium

Functions

- Structural NA, phospholipids
- Modified saccharides, phosphoproteins, cofactors, G proteins
- Macroergic compounds (ATP)
- Regulatory role signaling cascade, energetic processes

Kidneys

- Reabsorption - proximal tubule (85 %) - Npt1-3



Vitamin D

PTH

IGF-1

FGF23

Magnesium

Distribution

- 1 mol bones approx. 54 %, muscles and soft tissues approx. 56 %
- ECF 0.5 mM

Blood

- $-0.7-1 \, \text{mM}$
- Approx. 30 % in protein complexes
- 15 % in phosphate and low molecular weight anion complexes
- 55 % free

Cell


- 95 % in ATP and similar molecules
- Concentration 0.5 mM
- Ion channels?

Kidneys

- 95 % of filtered amount is reabsorbed
- 15 % PT, 70 % cortical TAHL, 10 % DT
- Regulation magnesemia, calcamia, ECF volume


Functions


- Cofactor (glycolytic, kinase and phosphatase systems)
- Stabilizing function (DNA, RNA, ribosomes)
- Activator of ATP transporters
- Neuromuscular excitability




Collagen type I = most important protein of bone matrix


Bone matrix and bone mineral







Collagen and its synthesis



Mineralization

= production of small hydroxyapatite crystals (Ca, phosphates, carbonates, Mg, Na, K)

External mechanism – alkalic phosphatase

Deposition of calcium

Endopeptidases, PHEX – FGF23

Ca, P, and AF availability

Vesicle formation (matrix)

Collagen and its arrangement

Internal mechanism – phospho1 (Phosphoethanolamine/ phosphocholine phosphatase)

Cleavage of pyrophosphate


Phosphate availability for mineralization

SIEBLINGs

- Osteopontin, DMP-1 (OC)
- Bone sialoprotein, MEPE

Diet, calcium in diet, calcium/phosphorus in ECF

Bone tissue and its remodeling




Bone tissue and its remodeling

Osteocytes (OC)

- Metabolic activity
- PTH receptors
- Communication with bone surface
- Mechanic sensing
- RANKL production
- Direct degradation of bone tissue (osteocytic osteolysis)
- Adaptive remodeling

Osteoblasts (OB)

- Bone matrix production
- Production of collagen and noncollagen peptides + their orientation
- Regulation by hormones, local factors and cytokines
- Differentiation and further fate apotosis, osteocytes, lining cells
- "recruitment" of other cells IGF 1, IGF-2, TGF-β



Lining cells

- Stimulation of OB differentiation
- OC communication
- Differentiation to OB stimulated by PTH

Osteoclasts (OK)

 Bone tissue reabsorption

Osteoclasts


Key factor regulating bone resorption is RANKL/OPG ratio.

Production of mixture of pro- and anticlastogenic factors (differences in time)


E2 (estrogens) – inhibition of T cell activation= inhibition of RANKL and TNF-α secretion

Sex hormones – regulation of osteoblasts and osteoclasts differentiation, including length of their life

Expression of different receptors in time (effect of various stimuli)



Bone tissue resorption by osteoclasts



Role of compartmentalization in bone resorption - *podosomes*

Resorption and secretion of bone resorption products - transcytosis

Essential role of pH for bone tissue resorption

Factors affecting bone tissue remodeling

Resorption takes approx. 2 weeks
Mineralization and formation approx. 12 weeks

In pathophysiologic conditions is disrupted the continuity of bone tissue resorption and formation.

Cytokines - IL-1 α , IL-1 β , TNF- α , TNF- β , proinflammatory IL (7, 15, 17)

TGF- α and EGF, FGF21, FGF23

Prostaglandins

PDGF


Cytokines - IL-4, IL-13, IL-10, IL-18

Prostaglandins

VEGFA, HIF-1 α (+/-)

IGF-1 (endo-/paracrine)

BMPs (OB, autocrine)




Ensuring mechanical requirements

Trabecular bone

Endocrine regulation of bone tissue

Hormone	Effect	Target cells
PTH	 Stimulation of resorption (long-term effect) Stimulation of bone formation (pulsatile effect) Stimulation of local secretion of IL-1 and IL-6 	Osteoblasts, lining cells, osteocytes
Vitamin D	 Stimulation of resorption (higher concentration) Inhibition of mineralization (higher concentration) Stimulation of bone formation (low concentrations, with PTH) 	Osteoblasts (primarily)
Calcitonin	Inhibition of resorptionRegulation of bone tissue remodeling	Osteoclasts
Growth hormone IGF-1	 Stimulation of bone turnover Stimulation of osteoblast proliferation and differentiation Increased synthesis of collagen and other proteins 	Osteoblasts – primarily GH Osteoblasts and osteoclasts – IGF-1
Glucocorticoids	 Decreased absorption of Ca in GIT Induction of osteoclastogenesis Increased bone resorption (+ RANKL) Suppressed remodeling of bone tissue Induction of apoptosis in osteoblasts and osteocytes Inhibition of IGF-1 synthesis 	Osteoblasts, osteocytes, osteoclasts
Thyroid hormones	 Children – Stimulation of mineralization and epiphyseal maturation Adults – increased resorption Chondrocyte growth and proliferation (permissive effect on growth hormone) Increased transcription of collagenase and gelatinase 	Osteoblasts, osteoclasts (also indirect through TSH)
Insulin	 Stimulation of bone tissue formation and mineralization Increased collagen synthesis Stimulation of IGF-1 secretion 	Primarily osteoblasts
Sex hormones	 Epiphyseal closure (E) Inhibition of RANKL secretion Changes in speed of bone resorption and formation (stimulation of formation and mineralization) 	Primarily osteoblasts, also other bone cells
Prolactin	- Indirect effect	

Insulin – osteocalcin axis





Bone tissue metabolism markers

 $\begin{array}{lll} \mbox{lonized calcium} & 8.5-10.5 \ \mbox{mg/dL} \\ \mbox{Plasmatic phosphates} & 3-4.5 \ \mbox{mg/dL} \\ \mbox{PTH} & 10-65 \ \mbox{pg/mL} \\ \mbox{Vitamin D} & 30-100 \ \mbox{ng/mL} \\ \end{array}$

Marker	Tissue origin	Analytical sample	Analytical method
Hydroxyproline, total and dialyzable (OH-Pro, OHP); specific for all fibrilar collagens and a part of collagen proteins, including Ciq and elastin; present in newly synthesized and mature collagen	bone, skin, cartilage, soft tissues	urine	colorimetry, HPLC
Pyridinoline (PYD, Pyr); high concentrations in cartilage and bone collagen: not present in skin; present only in mature collagen	bone, tendon, cartilage	urine	HPLC, ELISA
Deoxypyrindoline (DPD, d-Pyr); high concentrations only in bone collagen: not present in cartilage or in skin; present only in mature collagen	bone, dentine	urine	HPLC, ELISA
Cross-linked C-terminal telopeptide of type I collagen (ICTP); high proportion from bone collagen in type I collagen; can partly originate from newly synthesized collagen	bone, skin	serum	RIA
Cross-linked C-terminal telopeptide of type I collagen (fragments alpha-CTX, beta-CTX); in type I collagen; probably high proportion from bone collagen	all tissue con- taining type I collagen	urine, serum	ELISA, RIA, ECLIA
Cross-linked N-terminal telopeptide of type I collagen (fragments NTX); in type I collagen; big proportion from bone	all tissue con- taining type I collagen	urine (alpha/ beta), serum (only beta)	ELISA, RIA, ICMA
Hydroxylysine-glycosides (Hyl-Glyc); collagens and collagen proteins; glucogalactosyl- hydroxilysine is highly represented in soft tissue collagens and C1q; galactosil-OHLys is highly rep- resented in bone collagen	bone, skin, soft tissue, serum complement	urine	HPLC, ELISA
Bone sialoprotein (BSP); synthesized by active osteoblasts and lay in extracellular bone matrix; it seems to express osteoclast activity	bone, dentine, hypertrophic catrilage	serum	RIA, ELISA
Tartarat-resistant acid phosphatase (TR-ACP); osteoclasts, thrombocytes, erythrocytes	bone, blood	plasma/serum	colorimetry, RIA, ELISA
Free gamma carboxyglutamin acid (GLA); resulted from bone proteins (e.g. osteocalcin, matrix Gla protein) and from coagulation factor	blood, bone	serum/urine	HPLC
coagulation factor HPLC – high performance liquid chromatography; ELISA – enzyme-linked immunosor ECLIA – electrochemiluminiscence immunoassay; ICMA – immunochemiluminometric		o immuno assay;	

Clinical relevance


- Osteogenesis imperfecta
- Osteopetrosis
- Osteomalacia
- Rachitis
- Osteopenia T score -1 -2.5
- Osteoporosis T score under -2.5



Parathormone


Characteristics

- Parathyroid glands chief cells
 - Synthesis and storage of PTH
 - Very quick secretion of PTH
 - Ability to proliferate during long-term stimulation



PTH

- Synthetized as pre-pro-PTH
- Several types of secretion granules (PTH; PTH+cathepsin B, H)
- Very quick metabolization (70 % liver, 20 % kidneys) 2 min
- Presence of several types of fragments
- PTHR1, PTHR2, PTHR3 G prot.




PTH secretion


Cell proliferation of chief cells is an important adaptive mechanism for:


- Hypocalcemia
- Low levels of vitamin D(1,25(OH)₂D₃)
- Hyperphosphatemia (uremia)
- Neoplastic growth

Maximal secretion (reserve capacity)

Minimal secretion








Level of ionized calcium in blood is a key parameter for PTH secretion.

During sudden decrease of ionized calcium is PTH secretion increased.

Vitamin D decreases PTH secretion (inhibits expression and production of PTH), NOT during chronic hypocalcemia

Phosphates stimulate production and secretion of PTH with delay.

Calcium sensing receptors - CaSR - and PTH secretion



CaSR – G-protein coupled receptor

- Activation of PLC
- Inhibition of cAMP production

Various distribution in tissues – all tissues participating in calcium homeostasis

- Parathyroid glands
- Kidneys
- Skin
- GIT epithelium, enterocytes
- G cells of stomach
- CNS

Clinical aspects

- Mutation inactivation/activation
- familial hypocalciuric hypercalcemia (in.)
- Familial hypoparathyroidism with hypercalciuria (ac.)
- Calcimimetics inhibition of PTH secretion


Main effects of PTH

(+) calcium resorption


- cTAHL, DT
- transcellular and paracellular transport
- TRPV5 and TRPV6 Ca²⁺ inhibition
- Calbindin-D28K
- NCX1 and PMCA

(+) phosphate excretion

- PT and DT
- Inhibition of resorption
- NaPi cotransporters internalization, degradation
- (+) activity of 1α -hydroxylase PT
- (-) resorption of Na, water and bicarbonate PT
- (-) Na⁺/K⁺-APTase (basolateral membrane)
- (+) gluconeogenesis PT
- (-) GFR podocytes



PTH and bone tissue physiology



Effect of PTH on osteoclasts is indirect. Pulsatile secretion stimulates osteoblasts, chronic continual osteoclasts.


Parathyroid Hormone-Related Peptide - PTHrP

Characteristics

- First as a peptide produced by tumors endocrine effect – kidneys + bones
- Also paracrine local increase of Ca concentration
- Later discovered in many tissues

Functions

- Calciotropic hormone
- Fetal development proliferation and differentiation
- Lactation (+) resorption of bone tissue without possibility to affect by Ca supplementation
- Skin proliferation and differentiation
- GIT, bladder, uterus (+) smooth muscles relaxation
- CNS neuroprotection
- Para-/auto-/intracrine effect



Calcitonin

Characteristics

- C cells of thyroid gland
- Family of peptides (amylin, CGRPs, adrenomedulin)
- Different distribution in various tissues
- Secretion is determined by level of ionized calcium (CaSR)
- Stimulation of secretion:
 - Glucocorticoids
 - CGRP
 - Glucagon
 - Enteroglucagon
 - Gastrin
 - Pentagastrin
 - Pancreozymin
 - β-sympatomimetics
- Inhibition of secretion somatostatin

Functions

- Bone tissue
 - Inhibition of osteoclast motility and differentiation
 - Inhibition of osteoclast secretion
 - ATPase inhibition
- Kidneys

Function unclear

- Increased excretion of Ca inhibition of resorption
 (Ca²⁺ ion channels LS, Na⁺/Ca²⁺ BM)
- Skeleton development?
- Skeleton protection during pregnancy?

Clinical relevance

- Osteoporosis therapy
- Paget disease therapy
- Treatment of pain (bones metastases)
- ! Increased risk of cancer

Vitamin D....hormone?...vitamin?

Characteristics

- Intake with diet or synthesized (UV)
- In blood bound to VDBP and albumin
- Very small free fraction 1,25(OH)₂D cca 0,4 %

Estrogens (+)


PTH, prolactin, calcitonin, GH (+) T3/T4, metabolic acidosis (-) Ca, phosphates, 1,25(OH)₂D, FGF23 (-) Ketoconazole

1α -hydroxylase

- Expression in various tissues
- Keratinocytes
- Placenta
- Macrophages

Different rate of feedback control

Different 1α -hydroxylase expression = local tissue homeostasis



Physiological effects of vitamin D

VDR

- High affinity to 1,25(OH)₂D
- Level of circulating 1,25(OH)₂D
- Heterodimer with RXR coactivators, corepressors

Non-genomic effects

- Rapid increase of intracellular Ca concentration
- PLC activation
- Opening of some Ca ion channels
- Required VDR presence

Vitamin D and Ca absorption/reabsorption

- (+) CBP, AP, Ca²⁺/Mg²⁺-ATPase
- (+) TRPV6 absorption (GIT)
- (+/-) TRPV5 reabsorption (kidneys)
- Calbindin-9K
- 1,25(OH)₂D-inducible ATP-dependent Ca²⁺ pump
- Na⁺/Ca²⁺ exchanger

Parathyroid glands

- Gene expression regulation
- Cell proliferation regulation
- (-) PTH gene transcription

Bones and bone tissue

- (-) collagen synthesis
- (+) osteocalcin synthesis
- (+) osteoclasts differentiation osteoclastogenesis
- (+) RANKL
- Main function ensuring the stability of the bone microenvironment for mineralization by the standard intake and availability of Ca and phosphates

Muscle tissue


- (+) uptake AAs
- (+) troponin C
- Phospholipids metabolism

Vitamin D and immune system

Clinical relevance

- Analogue of vitamin D without ability to cause hypercalcemia
- Antiproliferative effect treatment of cancer?
- Synergy with cyclosporin B rejection of transplantates
- Suppression of PTH synthesis –
 22-oxacalcitriol (hyperparathyroidismus)
- Psoriasis (clinical trials)

Macrophages Dendritic cells T cells



FGF23 – fibroblast growth factor 23

Characteristics

- New hormone?
- Overexpression = hypophosphatemia and decrease of 1α 25(OH)D hydroxylation

Functions


- maintaining normophosphatemia and regulation of vitamin D metabolism
- IncrDecreased expression of IIa, IIb, and IIc (NPT) –
 phosphate transport
- eased expression of 24-hydroxylase inactive form
- Klotho = co-receptor

Regulation

- Phosphorus availability in diet (-)
- Serum phosphorus
- 1,25(OH)₂D
- iron

Clinical relevance:

- Autosomal dominant hypophosphatemic rickets (ADHR)
- Tumor-induced osteomalacia (TIO)
- Klotho mutation
- Prediction of chronic kidney failure prognosis



Calcium homeostasis – still just a simplified model

